General Information of Drug (ID: DMVDCGZ)

Drug Name
Pyridoxamine Drug Info
Synonyms Pyridorin (TN)
Indication
Disease Entry ICD 11 Status REF
Diabetic kidney disease GB61.Z Phase 3 [1]
Diabetic nephropathy GB61.Z Phase 3 [1]
Cross-matching ID
PubChem CID
1052
ChEBI ID
CHEBI:16410
CAS Number
CAS 85-87-0
TTD Drug ID
DMVDCGZ
INTEDE Drug ID
DR1911

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Advanced glycosylation end product receptor (AGER) TTMO9HF RAGE_HUMAN Inhibitor [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID Highest Status REF
Pyridoxamine-phosphate oxidase (PNPO) DE3Z1RA PNPO_HUMAN Phase 3 [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Advanced glycosylation end product receptor (AGER) DTT AGER 4.347 2.379 1.945 4.233
Pyridoxamine-phosphate oxidase (PNPO) DME PNPO 7.731 6.545 7.291 7.208
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Diabetic kidney disease
ICD Disease Classification GB61.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Advanced glycosylation end product receptor (AGER) DTT AGER 7.92E-01 6.77E-03 0.04
Pyridoxamine-phosphate oxidase (PNPO) DME PNPO 2.99E-02 -1.61E-01 -6.72E-01
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02156843) Pyridorin in Diabetic Nephropathy. U.S. National Institutes of Health.
2 Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice. Protein Pept Lett. 2010 Sep;17(9):1177-81.
3 An LC-MS/MS-based method for the quantification of pyridox(am)ine 5'-phosphate oxidase activity in dried blood spots from patients with epilepsy. Anal Chem. 2017 Sep 5;89(17):8892-8900.